 |
Vol.57 No.7 contents | Japanese/English |
 | Full Text of PDF (883K) Article in Japanese |
- Invited Review Article -
Current Treatment Strategies for Lung Cancer Combined with Interstitial Lung Diseases
Toshihiko Sato11Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Japan
Interstitial lung diseases (ILDs) frequently occur with lung cancer. Anticancer therapy may provoke the acute exacerbation of interstitial pneumonia (AE), which is a potentially fatal complication. After Yoshimura et al. proposed the diagnostic criteria of AE for therapeutic interventions, the importance of this serious complication became widely understood. ILDs themselves are well-characterized as an entity, and advances in research have been made concerning their outcomes and prognoses. The poor prognosis associated with ILDs is widely recognized. Currently, the risk of severe AE is present in all anticancer therapies (including surgical resection, chemotherapy, and radiation therapy), and a more cautious approach is required. As research on the AE incidence, risk factors, and treatment outcomes continues to progress, oncologists have entered a new phase. With the accumulation of knowledge on preventive care, there is a trend toward advancements in treatment with evidence-based precautions. In light of such trends, this article outlines the recent anticancer therapies for lung cancer patients with ILDs.
key words: Lung cancer, Interstitial pneumonia, Surgical resection, Radiation therapy, Chemotherapy
JJLC 57 (7): 819-825, 2017
